Pfizer Hands UCART19, Allogenic CAR-T Portfolio Rights to $300M Startup

Pfizer will contribute its lead allogenic chimeric antigen receptor T-cell (CAR-T) candidate UCART19, licensed from Servier—as well as 16 preclinical CAR-T candidates licensed from Servier and Cellectis—to a cancer-fighting startup created with $300 million in financing to advance development of the therapies.Pfizer has taken a 25% stake in the new company, Allogene Therapeutics, which will have exclusive rights to develop and commercialize UCART19